2026 Interim report
Filed with HKEX · Stock code 6978 · · 64 pages · English
Immunotech Biopharm Ltd on 6ix
Earlier from Immunotech Biopharm
- Major transaction further delay in despatch of circular in relation to the construction of the new biological drug R&D and industrialisation based in beijing
- Change of senior management
- Immunotech Biopharm: Major transaction construction agreement in relation to the construction of the new biological drug R&D and industrialisation base in beijing
- Voluntary announcement establishment of and investment in cellular immunotherapy specialised industry fund as a limited partner
Later from Immunotech Biopharm
- Supplemental announcement to the annual report for the year ended 31 December 2025
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Placing of new shares under general mandate
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
Follow Immunotech Biopharm into a list and get an email when it puts out news.
Follow Immunotech Biopharm